FDA wants to relax criteria for Alzheimer's drug approval, NY Times says

theflyonthewall.com

The FDA intends to make it easier for companies to obtain approval of new treatments for Alzheimer’s disease, according to The New York Times. Under the agency's proposal, drugs could be approved if they improve peoples' performance on cognitive tests even before symptoms become apparent, and companies would not have to demonstrate that their drugs improve patients' functioning, the newspaper explained. Currently companies must show that their drugs improve patients' day to day functioning in order to obtain FDA approval of treatments, The Times added.

View Comments